Kernel 1.0

  • Back online…

    Back online… The TDI Web page is finally hosted again at the Structural Genomics Group. We are now working to put online the Kernel for TDI… stay tuned.

  • TDI featured in

    TDI featured in Today we have been featured at the Spanish main Medical daily journal Diario Médico. You can read more 20110715_DM_page13 (Spanish).

  • Yet… more good news for TDI!

    We have been awarded a couple of grants! Our research group (Marti-Renom) has been awarded with a Spanish grant to work on RNA target identification for NTDs, which results will end as part of the TDI kernel. Moreover, we will also coordinate a EU grant (a EraNet Pathogenomics) in collaboration with GlaxoSmithKline (LLuís Ballell), Pasteur [...]

  • More good news to Open Source Drug Discovery

    Mat Todd will be doing “Medicinal Chemistry Without Borders”! Our good friend Mat Todd has been able to coordinate efforts with MMV to optimize lead compounds provided by MMV, while encouraging others around the world to participate. By “others” they mean anybody – undergrads, grads, industry guys. In fact, they will need both medchem advice [...]

  • More good news for tropical disease research!

    New active compounds against Malaria from the GSK libraries GlaxoSmithKline (GSK) screened nearly 2 million compounds from their chemical library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 mM concentration. More than 8,000 also showed potent activity against the multidrug resistant strain Dd2. [...]

  • Open Science discussed in Chemistry in Australia

    Open Science discussed in Chemistry in Australia Our friend Matthew Todd talks about Open Science in general in this Q & A in the Chemistry in Australia Journal. You can read more here.

  • TDI featured in

    TDI featured in Tatum Anderson has written a nice piece on Open Source Drug Discovery. She has covered and compared our TDI efforts within a more general OSDD approach. You can read more here.

  • Good news for Tropical Disease Research!

    New collaboration between Pfizer and DNDi. Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to [...]

  • Blogging about TDI’s kernel start appearing…

    Common Knowledge blog post We are glad to see that our kernel is starting to spark some comments and posts in the blogsphere. For example, John Wilbanks, who runs the Science Commons project at Creative Commons, has some nice thoughts on our approach.

In brief...

The Tropical Disease Initiative aims to provide a "kernel" for open source drug discovery. Such kernel should allow scientists from laboratories, universities, institutes, and corporations to work together for a common cause: find new drugs against tropical disieases such as Malaria or Tuberculosis.
To know more, visit the "INSIDE" links... →